Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Hong Kong · Delayed Price · Currency is HKD 9.28
+0.08 (0.87%)
Jul 18, 2025, 3:58 PM HKT
Wenzhou Kangning Hospital Revenue
In the year 2024, Wenzhou Kangning Hospital had annual revenue of 1.65B CNY with 3.63% growth. Wenzhou Kangning Hospital had revenue of 825.33M in the half year ending December 31, 2024, with 10.55% growth.
Revenue
1.65B CNY
Revenue Growth
+3.63%
P/S Ratio
0.38
Revenue / Employee
339.76K CNY
Employees
4,869
Market Cap
661.31M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.65B | 58.02M | 3.63% |
| Dec 31, 2023 | 1.60B | 111.36M | 7.50% |
| Dec 31, 2022 | 1.48B | 187.47M | 14.45% |
| Dec 31, 2021 | 1.30B | 308.42M | 31.18% |
| Dec 31, 2020 | 989.01M | 128.32M | 14.91% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |